atracurium has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farina, N; Ingebrigtson, M; Kenes, M; McSparron, JI; Miller, J; Renius, K | 1 |
| Sohn, JT | 1 |
| Aubrun, F; Delignette, MC; Dziadzko, M; Mazard, T; Wallet, F; Ziatkowski-Michaud, J | 1 |
| Groskreutz, D; Hamid, K; Hamza, M; Sathyanarayanan, SP | 1 |
4 other study(ies) available for atracurium and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Cisatracurium Dosing Requirements in COVID-19 Compared to Non-COVID-19 Patients.
Topics: Atracurium; COVID-19; Humans; Infusions, Intravenous | 2023 |
Malignant Hyperthermia and Cisatracurium During Severe SARS-CoV-2 Infection.
Topics: Atracurium; COVID-19; Humans; Malignant Hyperthermia; SARS-CoV-2 | 2022 |
Neuromuscular monitoring and neuromuscular blocking agent shortages when treating critically ill COVID-19 patients: a multicentre retrospective analysis.
Topics: Atracurium; COVID-19; Critical Illness; Humans; Neuromuscular Blocking Agents; Neuromuscular Monitoring; Retrospective Studies; SARS-CoV-2 | 2021 |
Cisatracurium-Associated Malignant Hyperthermia During Severe Sars-CoV-2 Infection.
Topics: Atracurium; COVID-19; Dyspnea; Humans; Male; Malignant Hyperthermia; Middle Aged; Neuromuscular Blocking Agents; SARS-CoV-2 | 2021 |